• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by iRadimed Corporation

    5/14/26 5:16:54 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care
    Get the next $IRMD alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    IRADIMED CORPORATION

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)



    (CUSIP Number)


    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP No.


    1Names of Reporting Persons

    Roger E. Susi
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    162,950.00
    6Shared Voting Power

    4,287,500.00
    7Sole Dispositive Power

    162,950.00
    8Shared Dispositive Power

    4,287,500.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,450,450.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    34.8 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Rows 5 and 7 represent 162,950 shares of common stock (the "RT Shares"), par value $0.0001 per share ("Common Stock"), of Iradimed Corporation (the "Issuer") held by the Roger E. Susi Revocable Trust ("RT"). Roger E. Susi is the settlor and trustee of RT. Row 6 and 8 represent 2,062,500 shares of Common Stock (the "MT Shares") held by the Matthew Susi 2008 Dynasty Trust ("MT") and 2,225,000 shares of Common Stock (the "PT Shares") held by the Phillip Susi 2008 Dynasty Trust ("PT"). Roger E. Susi is the settlor for each of MT and PT, which are irrevocable, but for which Roger Susi holds rights as the settlor to substitute the assets of MT and PT in certain circumstances. J. Richard Susi, the brother of Roger Susi, is the trustee for each of MT and PT. Row 9 represents (i) the RT Shares plus (ii) the MT Shares plus (iii) the PT Shares. Row 11 percentage is calculated based upon 12,783,035 shares of Common Stock outstanding of the Issuer as of April 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 1, 2026 (the "Form10-Q").


    SCHEDULE 13G

    CUSIP No.


    1Names of Reporting Persons

    Roger E. Susi Revocable Trust
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    FLORIDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    162,950.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    162,950.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    162,950.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.3 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Rows 5, 7, and 9 represent the RT Shares. Roger E. Susi is the settlor and trustee of RT. Row 11 percentage is calculated based upon 12,783,035 shares of Common Stock outstanding of the Issuer as of April 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 1, 2026 (the "Form10-Q").


    SCHEDULE 13G

    CUSIP No.


    1Names of Reporting Persons

    Matthew Susi 2008 Dynasty Trust
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    FLORIDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,062,500.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,062,500.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,062,500.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    16.1 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Rows 5, 7, and 9 represent the MT Shares. Roger E. Susi is the settlor of MT which is irrevocable, but for which Roger Susi has rights as the settlor to substitute the assets of MT in certain circumstances. J. Richard Susi, the brother of Roger Susi, is the trustee of MT. Row 11 percentage is calculated based upon 12,783,035 shares of Common Stock outstanding of the Issuer as of April 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 1, 2026 (the "Form10-Q").


    SCHEDULE 13G

    CUSIP No.


    1Names of Reporting Persons

    Phillip Susi 2008 Dynasty Trust
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    FLORIDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,225,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,225,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,225,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    17.4 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Rows 5, 7, and 9 represent the PT Shares. Roger E. Susi is the settlor of PT which is irrevocable, but for which Roger Susi has rights as the settlor to substitute the assets of PT in certain circumstances. J. Richard Susi, the brother of Roger Susi, is the trustee of PT. Row 11 percentage is calculated based upon 12,783,035 shares of Common Stock outstanding of the Issuer as of April 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 1, 2026 (the "Form10-Q").


    SCHEDULE 13G

    CUSIP No.


    1Names of Reporting Persons

    J. Richard Susi
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    4,287,500.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    4,287,500.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,287,500.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    33.5 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Row 6, 8, and 9 represent (i) the MT Shares plus (ii) the PT Shares. Row 11 percentage is calculated based upon 12,783,035 shares of Common Stock outstanding of the Issuer as of April 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 1, 2026 (the "Form10-Q").


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    IRADIMED CORPORATION
    (b)Address of issuer's principal executive offices:

    12705 Ingenuity Drive, Orlando, Florida, 32826
    Item 2. 
    (a)Name of person filing:

    Each of the folowing is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons". This statement is filed on behalf of: (i) Roger E. Susi (ii) Roger E. Susi Revocable Trust ("RT") (iii) Matthew Susi 2008 Dynasty Trust ("MT") (iv) Phillip Susi 2008 Dynasty Trust ("PT") (v) J. Richard Susi
    (b)Address or principal business office or, if none, residence:

    Each Reporting Person's address is c/o Iradimed Corporation, 12705 Ingenuity Drive, Orlando, Florida 32826
    (c)Citizenship:

    Each of Messrs. Roger E. Susi and J. Richard Susi is a citizen of the United States of America. RT is a Florida Trust. MT is a Florida Trust. PT is a Florida Trust.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Items 4(a)-(c) with respect to each Reporting Person is set forth in Rows 5-11 of the applicable cover page hereto, and is incorporated herein by reference.
    (b)Percent of class:

    Each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of shares of Common Stock listed on such Reporting Person's cover page, calculated under Rule 13d-3 of the Securities Exchange Act of 1934, as amended. Calculations are based on 12,783,035 shares of Common Stock outstanding as of April 30, 2026, as set forth in the Issuer's Quarterly Report for the quarterly period ended March 31, 2026 filed with the U.S. Securities Exchange Commission on May 1, 2026.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See the information set forth in Row 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See the information set forth in Row 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See the information set forth in Row 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See the information set forth in Row 8 on each cover page.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Roger E. Susi
     
    Signature:/s/ Roger E. Susi
    Name/Title:Roger E. Susi
    Date:05/14/2026
     
    Roger E. Susi Revocable Trust
     
    Signature:/s/ Roger E. Susi
    Name/Title:Roger E. Susi
    Date:05/14/2026
     
    Matthew Susi 2008 Dynasty Trust
     
    Signature:/s/ J. Richard Susi
    Name/Title:J. Richard Susi
    Date:05/14/2026
     
    Phillip Susi 2008 Dynasty Trust
     
    Signature:/s/ J. Richard Susi
    Name/Title:J. Richard Susi
    Date:05/14/2026
     
    J. Richard Susi
     
    Signature:/s/ J. Richard Susi
    Name/Title:J. Richard Susi
    Date:05/14/2026
    Get the next $IRMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRMD

    DatePrice TargetRatingAnalyst
    4/12/2023$50.00Buy
    Lake Street
    More analyst ratings

    $IRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Scharen-Guivel Hilda Frederique sold $285,000 worth of shares (3,000 units at $95.00), decreasing direct ownership by 35% to 5,598 units (SEC Form 4)

    4 - IRADIMED CORP (0001325618) (Issuer)

    6/4/26 4:21:52 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    CEO, President, Chairman Susi Roger E. sold $226,507 worth of shares (2,500 units at $90.60) as part of a pre-agreed trading plan (SEC Form 4)

    4 - IRADIMED CORP (0001325618) (Issuer)

    6/2/26 2:26:16 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    CEO, President, Chairman Susi Roger E. sold $691,044 worth of shares (7,500 units at $92.14) as part of a pre-agreed trading plan (SEC Form 4)

    4 - IRADIMED CORP (0001325618) (Issuer)

    5/28/26 3:08:17 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    $IRMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

    ORLANDO, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), a leader in developing innovative MRI-compatible medical devices, today announced that Roger Susi, President and Chief Executive Officer, and Jack Glenn, Chief Financial Officer, will attend the Goldman Sachs 47th Annual Global Healthcare Conference, to be held June 8–10, 2026, at the Loews Miami Beach Hotel, Miami Beach, Florida. Investors interested in meeting with Iradimed management during the conference may contact their Goldman Sachs representative to schedule a one-on-one meeting. About IRADIMED CORPORATION IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging ("MRI"

    5/20/26 8:30:00 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    IRADIMED CORPORATION Reports First Quarter 2026 Financial Results

    Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance  Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025.Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the first quarter of 2026, which are increases of 22% and 17%, respectively, compared to the same period in 2025.Declares a regular quarterly cash dividend of $0.20 per share of common stock for the second quarter of 2026, payable on May 29, 2026. ORLANDO, Fla., May 01, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company" or "Iradimed") (NASDAQ:IRMD)

    5/1/26 8:30:00 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    IRADIMED CORPORATION to Hold First Quarter 2026 Financial Results Conference Call on May 1, 2026

    ORLANDO, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2026 first quarter financial results before the market opens on Friday, May 1, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI7676b33322324840ad2b154cc8e65b88. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-time

    4/27/26 8:30:00 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    $IRMD
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by iRadimed Corporation

    SCHEDULE 13G/A - IRADIMED CORP (0001325618) (Subject)

    5/14/26 5:16:54 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by iRadimed Corporation

    10-Q - IRADIMED CORP (0001325618) (Filer)

    5/1/26 4:08:46 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    iRadimed Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - IRADIMED CORP (0001325618) (Filer)

    5/1/26 8:45:28 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    $IRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on iRadimed with a new price target

    Lake Street initiated coverage of iRadimed with a rating of Buy and set a new price target of $50.00

    4/12/23 9:17:10 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    $IRMD
    Leadership Updates

    Live Leadership Updates

    View All

    IRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors

    WINTER SPRINGS, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company") (NASDAQ:IRMD) today announced the appointment of Hilda Scharen-Guivel to the Iradimed Board of Directors, effective October 4, 2022. Following the appointment of Ms. Scharen-Guivel, the Board will comprise five directors, three of whom are independent. "We are pleased to welcome Hilda Scharen-Guivel to the Iradimed Board," said Roger Susi, President and Chief Executive Officer of the Company. "Hilda's deep experience in regulatory oversight in the medical device industry will be invaluable to Iradimed as we develop new products and grow our business to better serve patients." Ms. Scharen-Guivel,

    10/6/22 4:05:00 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    Perimeter Medical Imaging AI Appoints Experienced MedTech Executive, Chris Scott, as Chief Financial Officer

    Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(OTC:PYNKF) (FSE:4PC) ("Perimeter" or the "Company"), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, today announced the appointment of Chris Scott as Chief Financial Officer, effective immediately. Jeremy Sobotta, Perimeter's Chief Executive Officer stated, "We are pleased to welcome Chris to the Perimeter leadership team. Chris is a collaborative leader who brings a wealth of public company experience directly relevant to Perimeter as we continue to execute on our commercial, clinical, and corporate development goals. Previously

    6/1/22 9:35:00 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    $IRMD
    Financials

    Live finance-specific insights

    View All

    IRADIMED CORPORATION Reports First Quarter 2026 Financial Results

    Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance  Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025.Reports record GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49 for the first quarter of 2026, which are increases of 22% and 17%, respectively, compared to the same period in 2025.Declares a regular quarterly cash dividend of $0.20 per share of common stock for the second quarter of 2026, payable on May 29, 2026. ORLANDO, Fla., May 01, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company" or "Iradimed") (NASDAQ:IRMD)

    5/1/26 8:30:00 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    IRADIMED CORPORATION to Hold First Quarter 2026 Financial Results Conference Call on May 1, 2026

    ORLANDO, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2026 first quarter financial results before the market opens on Friday, May 1, 2026. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions. Individuals interested in participating in the conference call may do so by registering here, https://register-conf.media-server.com/register/BI7676b33322324840ad2b154cc8e65b88. Once registered, a dial-in number, unique pin, and instructions will be provided to participants. The conference call will also be available real-time

    4/27/26 8:30:00 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    IRADIMED CORPORATION Reports Record Fourth Quarter and Full Year of 2025 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.20 Per Share from $0.17 Per Share

    Reports record revenue of $22.7 million for the fourth quarter of 2025, an increase of $3.3 million, or 17%, compared to the same period in 2024. Reports record GAAP diluted EPS of $0.50 and non-GAAP diluted EPS of $0.54 for the fourth quarter of 2025, which are increases of 25% and 23%, respectively, compared to the same period in 2024. Reports record GAAP diluted EPS of $1.75 and non-GAAP diluted EPS of $1.93 for the full year of 2025, which are increases of 17% and 16%, respectively, compared to the full year of 2024. Declares a regular quarterly cash dividend of $0.20 per share of common stock for the fourth quarter of 2025, payable on March 6, 2026. ORLANDO, Fla., Feb. 10, 2026 (G

    2/10/26 8:00:00 AM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    $IRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by iRadimed Corporation

    SC 13G/A - IRADIMED CORP (0001325618) (Subject)

    11/14/24 3:35:27 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

    SC 13G/A - IRADIMED CORP (0001325618) (Subject)

    2/13/24 4:25:25 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by iRadimed Corporation (Amendment)

    SC 13G/A - IRADIMED CORP (0001325618) (Subject)

    2/12/24 12:03:30 PM ET
    $IRMD
    Medical/Dental Instruments
    Health Care